Department of Surgery, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Department of Radiation Oncology, Haeundae Paik Hospital, Inje University School of Medicine, 875 Haeundae-ro, Haeundae-gu, Busan, 48108, Republic of Korea.
Clin Transl Oncol. 2018 Aug;20(8):1011-1017. doi: 10.1007/s12094-017-1815-y. Epub 2017 Dec 18.
We investigated the role of adjuvant concurrent chemoradiation therapy (CCRT) in patients with a microscopically positive resection margin (R1) after curative resection for extrahepatic cholangiocarcinoma (EHCC).
METHODS/PATIENTS: A total of 84 patients treated with curative resection for EHCC were included. Fifty-two patients with negative resection margins did not receive any adjuvant treatments (R0 + S group). The remaining 32 patients with microscopically positive resection margins received either adjuvant CCRT (R1 + CCRT group, n = 19) or adjuvant radiation therapy (RT) alone (R1 + RT group, n = 13).
During the median follow-up period of 26 months, the 2-year locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival rates (OS) were: 81.8, 62.6, and 61.5% for R0 + S group; 71.8, 57.8, and 57.9% for R1 + CCRT group; and 16.8, 9.6, and 15.4% for R1 + RT group, respectively. Multivariate analysis revealed that the R1 + CCRT group did not show any significant difference in survival rates compared with the R0 + S group. The R1 + RT group had lower LRRFS [hazard ratio (HR) 3.008; p = 0.044], DFS (HR 2.364; p = 0.022), and OS (HR 2.417; p = 0.011) when compared with the R0 + S and R1 + CCRT group.
A lack of significant survival difference between R0 + S group and R1 + CCRT group suggests that adjuvant CCRT ameliorates the negative effect of microscopic positive resection margin. In contrast, adjuvant RT alone is appeared to be inadequate for controlling microscopically residual tumor.
我们研究了辅助同步放化疗(CCRT)在肝外胆管癌(EHCC)根治性切除术后显微镜下阳性切缘(R1)患者中的作用。
方法/患者:共纳入 84 例接受 EHCC 根治性切除术的患者。52 例阴性切缘患者未接受任何辅助治疗(R0+S 组)。其余 32 例显微镜下阳性切缘患者接受辅助 CCRT(R1+CCRT 组,n=19)或辅助放疗(R1+RT 组,n=13)。
在中位随访 26 个月期间,R0+S 组、R1+CCRT 组和 R1+RT 组的 2 年局部区域无复发生存率(LRRFS)、无病生存率(DFS)和总生存率(OS)分别为:81.8%、62.6%和 61.5%;71.8%、57.8%和 57.9%;16.8%、9.6%和 15.4%。多因素分析显示,R1+CCRT 组与 R0+S 组的生存率无显著差异。与 R0+S 组和 R1+CCRT 组相比,R1+RT 组的 LRRFS(风险比[HR]3.008;p=0.044)、DFS(HR 2.364;p=0.022)和 OS(HR 2.417;p=0.011)均较低。
R0+S 组与 R1+CCRT 组之间生存差异无统计学意义,提示辅助 CCRT 可减轻显微镜下阳性切缘的负面影响。相反,单独辅助放疗似乎不足以控制显微镜下残留肿瘤。